SPOTLIGHT: CellCept wins orphan status

The FDA has granted orphan drug status to the immunosuppressant CellCept, being developed by Roche and Aspreva. CellCept is currently in a late-stage trial for Myasthenia Gravis, a rare immune system ailment. Report